Posted by Michael Wonder on 04 Jan 2021
Ibrutinib with rituximab in previously untreated chronic lymphocytic leukaemia: indication of added benefit over FCR
4 January 2020 - The new drug combination prolongs overall survival in patients in good general health. No study data are available for other patient groups.
The combination of ibrutinib plus rituximab is approved for the treatment of adults with previously untreated chronic lymphocytic leukaemia.
In an early benefit assessment, the German IQWiG now examined which advantages and disadvantages this drug combination has for the patients.
